High neuronatin (NNAT) expression is associated with poor outcome in breast cancer
Neuronatin (NNAT) is a proteolipid involved in cation homeostasis especially in the developing brain. Its expression has been associated with the progression of lung cancer, glioblastoma, and neuroblastoma as well as glucose induced apoptosis in pancreatic cells. We performed a retrospective study of 148 breast cancer specimens for NNAT expression by immunohistochemistry to evaluate this protein as a prognostic marker for breast cancer. We found a high NNAT immunoreactivity score (by multivariate cox regression) to be an independent prognostic marker for relapse-free (hazard ratio HR = 3.55, p = 0.002) and overall survival (HR = 6.29, p < 0.001). However, NNAT expression was not associated with classical parameters such as hormone receptor expression (p = 0.86) or lymph node metastasis (p = 0.83). Additional independent risk factors in this study population were tumor size (≤2 cm; overall survival: HR = 0.36, p = 0.023; relapse-free survival: HR = 0.26, p < 0.01) and blood vessel infiltration (overall survival: HR = 0.34 p < 0.01). NNAT expression determined by immunohistochemistry might therefore become a helpful additional biomarker to identify high-risk breast cancer patients.
KeywordsBreast cancer Neuronatin Immunohistochemistry Prognosis
Parts of this study have been supported by a grant of the Deutsche Forschungsgemeinschaft (DFG) to T.K. (KA2663/3-1). Professional assistance of our immunohistological laboratory, especially Carola Kügler, Claudia Miethke, and Nadine Wiest, is greatly appreciated.
Compliance with ethical standards
This study was funded by a grant of the Deutsche Forschungsgemeinschaft (DFG) to T.K. (KA2663/3-1).
Conflict of interest
The authors declare that they have no conflict of interest.
- 28.Buus R, Sestak I, Kronenwett R et al (2016) Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. doi: 10.1093/jnci/djw149
- 31.Hernández-Bedolla MA, González-Domínguez E, Zavala-Barrera C et al (2016) Calcium-sensing-receptor (CaSR) controls IL-6 secretion in metastatic breast cancer MDA-MB-231 cells by a dual mechanism revealed by agonist and inverse-agonist modulators. Mol Cell Endocrinol 436:159–168. doi: 10.1016/j.mce.2016.07.038 CrossRefPubMedGoogle Scholar